• The database table for Search and "New Messages" functionality is currently being rebuilt. Until it is completed, you may see empty or incomplete results for these.

Bluelight Census 2018

Global Drug Survey has partnered with Bluelight to create a sample of people who reported using Bluelight in the last 7 days.
This report is based on the data from 1480 people who used Bluelight in the last 7 days and completed GDS up to and including questions about novel substance use.
The survey was live in November-December 2017.

Summary of results:
  • Most Bluelighters (70% ) come from English-speaking countries (US, UK, Australia, Canada)
  • Bluelighters are typically young 'white' males (median age 20, 84% male, 88% 'White')
  • Over half of Bluelighters are currently studying (56% )
  • A quarter (24% ) have completed a university qualification
  • Half (51% ) report being in paid employment, including 28% that work full-time
  • 20% report their occupation as 'professional'
  • Almost half (45% ) report 'never' going clubbing
  • Lifetime drug use rates include 94% cannabis, 71% LSD and 68% MDMA
  • Lifetime use of prescription benzodiapines (64% ) and opioids (60% ) is significant
  • Lifetime rates of novel drug use are high, e.g. LSD analogues (21% ), novel benzos (21% )
  • Clearnet forums (such as Bluelight) are used extensively for harm reduction information
  • Almost all Bluelighterswho reported trying MDMA for the first time in the last 12 months used Bluelight to research MDMA beforehand
Limitations: the sample may not be representative of the Bluelight population and the results rely on accuracy of self-report.

Read/download the full report attached (PDF format):

Thanks to all of the community members who took the time to complete this survey.
Thanks also to Global Drug Survey for partnering with Bluelight in 2018.
Last edited by a moderator:
Thankyou for doing this. When do you think you you'll take another? There was a mention of an influx of new users since then, so 2021 might be a good time to canvas again.